<div id="readability-page-1">New insider activity at Exicure ( (XCUR) ) has taken place on January 21, 2026.<h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Significant shareholder HiTron Systems Inc. has unloaded 258,367 shares of Exicure stock in a recent transaction, with the sale totaling $1,162,651 in value. This sizable move by a major holder may draw attention from investors watching ownership changes and potential shifts in sentiment around Exicure. Recent Updates on XCUR stock Over the last 24 hours, Exicure’s stock activity has been driven primarily by clinical and presentation-related news rather than new financial data or formal analyst target revisions. The company announced it will present an encore poster at the 2026 Tandem Meetings, showcasing previously reported positive topline data from its open-label, multicenter Phase 2 trial of burixafor in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. The study focuses on burixafor’s ability to mobilize hematopoietic progenitor cells via CXCR4 blockade, a key mechanism for releasing stem cells from the bone marrow niche, which can improve the efficiency of stem cell collection for transplant. This clinically positive narrative, combined with recent trading volatility evidenced by a halt and subsequent resumption in Exicure’s stock, suggests that any recent or prospective price target adjustments by analysts would likely stem from reassessing the company’s clinical outlook and perceived probability of success for burixafor, as well as the strategic value of demonstrating consistent, reproducible trial data at a high-profile transplant and cellular therapy meeting, rather than from changes in earnings or broad market conditions. Spark’s Take on XCUR Stock According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral. The score is primarily constrained by weak financial performance (minimal revenue, ongoing net losses, and negative free cash flow), despite an improved balance sheet and reduced cash burn. Technicals are mixed with a modestly constructive intermediate trend but weakness versus the 200-day average, while valuation is not supported due to negative earnings and no dividend yield. To see Spark’s full report on XCUR stock, click here. More about Exicure YTD Price Performance: 13.28% Average Trading Volume: 697,737 Technical Sentiment Signal: Sell Current Market Cap: $39.65M</div>

XCUR

SBIO

On January 21, 2026, HiTron Systems Inc. sold 258,367 shares of Exicure (XCUR) for $1,162,651, raising investor interest in ownership changes. Exicure's stock activity has been influenced by clinical news, particularly regarding its Phase 2 trial of burixafor for multiple myeloma. Despite a positive clinical narrative, Spark's AI Analyst rates XCUR as Neutral due to weak financial performance and mixed technicals. The current market cap stands at $39.65M, with a year-to-date price performance of 13.28%.

Major Exicure Stakeholder Makes Bold Move With Large Share Sale